US Judge Dismisses Gautam Adani Criminal Charges 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
ADNOC Gas Targets Up to $4B Profit in 2026 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Thermo Fisher Scientific Inc., a leading U.S.-based medical equipment manufacturer, is reportedly close to finalizing an all-cash acquisition of clinical trial data management company Clario in a deal valued at around $10 billion, according to the Financial Times. While Reuters has not yet confirmed the report, sources suggest the announcement could come as early as Wednesday, provided no last-minute complications arise.
If completed, this would mark Thermo Fisher’s largest acquisition since its $17.4 billion purchase of contract research organization PPD in 2021. The deal underscores Thermo Fisher’s strategic push to expand its footprint in clinical research and digital health data management, sectors that have seen accelerated growth in recent years.
Clario, established in 2021 through the merger of health tech companies ERT and Bioclinica, provides advanced software solutions that help pharmaceutical companies manage and analyze clinical trial data efficiently. The company’s investors include private equity firms Nordic Capital and Astorg. Clario’s technology plays a vital role in streamlining drug development processes, making it an attractive acquisition target amid growing demand for AI-driven healthcare solutions.
Neither Thermo Fisher nor Clario has commented on the reported deal. However, the acquisition aligns with Thermo Fisher’s ongoing strategy of strengthening its portfolio through high-value takeovers. Earlier in 2024, the company announced plans to acquire Solventum’s purification and filtration business for approximately $4.1 billion, further enhancing its capabilities in life sciences and laboratory technologies.
With increasing global demand for laboratory tools and integrated data solutions, Thermo Fisher recently raised its annual profit and revenue forecasts, signaling confidence in its growth trajectory. The potential Clario acquisition would not only expand Thermo Fisher’s reach in clinical research but also reinforce its position as a global leader in healthcare innovation and biotechnology.
